Product Information
LUBIPROSTONE 8 MCG CAPSULE is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.5493 per EA under NDC 00480347906. Its NADAC has been published 183 times since Feb 22, 2023.
FDA first approved this application on Jan 18, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
8 ug/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00480347906
Classification
Generic
Dosage Form
CAPSULE, GELATIN COATED
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
LUBIPROSTONEApproval Type
Generic (ANDA)
FDA Application
ANDA209920FDA Approved
1/18/2022
TE Code
AB
On Market Since
1/3/2023
Pharmacological Classes
Price Statistics
The NADAC for LUBIPROSTONE 8 MCG CAPSULE has been published 183 times since Feb 22, 2023, and over the history we have for it it has declined 87.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5493 per EA |
|---|---|
| All-time high | $4.3426 (Mar 15, 2023) |
| All-time low | $0.5447 (Nov 20, 2024) |
| 52-week high | $0.8252 |
| 52-week low | $0.5493 |
| Median price | $0.7855 |
| Average price | $1.1075 |
| Largest weekly change | -46.8% (Dec 20, 2023) |
| Weeks tracked | 183 |
| Tracking since | Feb 22, 2023 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of LUBIPROSTONE 8 MCG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for LUBIPROSTONE 8 MCG CAPSULE, manufactured by Teva Pharmaceuticals USA Inc., is $0.5493 per EA (NDC 00480347906), effective Aug 19, 2026.
How has the price of LUBIPROSTONE 8 MCG CAPSULE changed over time?
Over the history we have for it, the NADAC for LUBIPROSTONE 8 MCG CAPSULE has declined 87.4%. It has been tracked across 183 weekly CMS publications since Feb 22, 2023.
What are the highest and lowest recorded NADAC prices for LUBIPROSTONE 8 MCG CAPSULE?
Since Feb 22, 2023, the NADAC for LUBIPROSTONE 8 MCG CAPSULE has ranged from a low of $0.5447 (Nov 20, 2024) to a high of $4.3426 (Mar 15, 2023), with a median of $0.7855 per EA.
Are there cheaper alternatives to LUBIPROSTONE 8 MCG CAPSULE?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LUBIPROSTONE 8 MCG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures LUBIPROSTONE 8 MCG CAPSULE?
LUBIPROSTONE 8 MCG CAPSULE (NDC 00480347906) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.